Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity.

Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity.

Publication date: Jun 16, 2024

While studies have suggested increased risks of severe COVID-19 infection in chronic obstructive pulmonary disease (COPD), the persistent and delayed consequences of COVID-19 infection on patients with COPD upon recovery remain unknown. A prospective clinical study was conducted in Hong Kong to investigate the persistent and delayed outcomes of patients with COPD who had COVID-19 infection of different severity (mild-moderate COVID-19 and severe COVID-19), compared with those who did not. Chinese patients with COPD ≥ 40 years old were recruited from March to September 2021. They were prospectively followed up for 24. 9 +/- 5. 0 months until 31st August 2023. The primary outcome was the deterioration in COPD control defined as the change in mMRC dyspnea scale. The secondary outcomes included the change in exacerbation frequency and non-COVID-19 respiratory mortality (including death from COPD exacerbation or bacterial pneumonia). 328 patients were included in the analysis. Patients with mild-moderate and severe COVID-19 infection had statistically significant increased risks of worsening of mMRC dyspnoea scale by increase in 1 score from baseline to follow-up with adjusted odds ratios of 4. 44 (95% CI = 1. 95-10. 15, p 

Open Access PDF

Concepts Keywords
August Aged
Copd40years COPD
Covid COPD control
Exacerbation COPD exacerbation
Pneumonia COVID-19
COVID-19
Disease Progression
Dyspnea
Female
Hong Kong
Humans
Male
Middle Aged
Prospective Studies
SARS-CoV-2

Semantics

Type Source Name
disease MESH chronic obstructive pulmonary disease
disease MESH COVID-19
disease MESH infection
pathway REACTOME Disease
disease IDO disease
disease VO frequency
disease MESH death
disease MESH bacterial pneumonia
drug DRUGBANK Coenzyme M
disease MESH pneumonia
disease MESH Asthma
pathway KEGG Asthma
disease VO volume
drug DRUGBANK Amlodipine
disease MESH abnormalities
disease MESH cognitive impairment
disease MESH post traumatic stress disorder
disease VO organ
disease MESH long COVID
disease IDO symptom
disease MESH syndrome
disease IDO acute infection
disease MESH bronchiectasis
disease IDO history
disease IDO blood
disease MESH sore throat
drug DRUGBANK Oxygen
drug DRUGBANK Medical air
disease MESH complications
disease VO dose
disease VO vaccination
disease MESH emergency
disease VO ANOVA
disease IDO disposition
drug DRUGBANK Gold
disease MESH morbidities
disease MESH Hypertension
disease MESH Diabetes mellitus
disease MESH stroke
disease MESH malignancies
disease MESH respiratory diseases
disease VO Optaflu
disease MESH influenza
disease MESH etiology
disease MESH organizing pneumonia
disease MESH fibrosis
disease VO report
disease MESH pertussis
pathway KEGG Pertussis
disease MESH acute respiratory distress syndrome
disease MESH lung injury
disease VO effectiveness
disease VO population
disease VO conjugate vaccine
disease MESH pneumococcal pneumonia
disease VO vaccine
disease MESH pneumococcal infection
disease MESH cardiovascular disease
disease MESH myocardial infarction
disease MESH Disease Progression

Original Article

(Visited 2 times, 1 visits today)